scispace - formally typeset
Journal ArticleDOI

Usefulness of Age (≥85 Years) and Residual Mitral Regurgitation (>1+/4+) for the Prediction of Adverse Outcomes in Patients Receiving the MitraClip.

TLDR
A reduced left ventricular end-diastolic volume and improved hemodynamics occurred early after MitraClip therapy, and an advanced age and residual MR >1+ were associated with an increased risk of mortality and heart failure.
Abstract
The goal of this study was to determine the predictors of adverse clinical outcomes in patients treated with the MitraClip for significant mitral regurgitation (MR) with a focus on acute changes in hemodynamics and cardiac function. This retrospective study included 63 patients (mean age 82 ± 8 years, 48% male) with moderate to severe or severe MR. Cardiac catheterization was performed before and immediately after MitraClip repair. Volumetric and functional changes were assessed in both ventricles. A major adverse cardiac event was defined as a composite of cardiac death and readmission for heart failure. Patients were followed up on average for 380 days. MR was improved in 92% of patients after MitraClip therapy from an average grade of 4+ to 1+ (p 1+ were associated with an increased risk of mortality and heart failure.

read more

Citations
More filters
Journal ArticleDOI

Transcatheter mitral valve repair is feasible and effective in oldest-old patients: results from real-world cohort.

TL;DR: In this paper , the authors evaluated the safety and efficacy of transcatheter mitral valve repair (TMVR) using MitraClip® devices in oldest-old patients compared to younger patients.
Journal ArticleDOI

Severe mitral regurgitation in nonagenarians: Impact of symptomatic status, frailty and etiology on management and outcomes.

TL;DR: In this paper , the authors assess symptomatic status, frailty, etiology and outcomes for nonagenarians with severe mitral regurgitation (MR) in extremely elderly patients.
References
More filters
Journal ArticleDOI

Transcatheter Mitral-Valve Repair in Patients with Heart Failure.

TL;DR: Among patients with heart failure and moderate‐to‐severe or severe secondary mitral regurgitation who remained symptomatic despite the use of maximal doses of guideline‐directed medical therapy, transcatheter mitral‐valve repair resulted in a lower rate of hospitalization forHeart failure and lower all‐cause mortality within 24 months of follow‐up than medical therapy alone.
Related Papers (5)